Goldman Sachs Group set a €74.50 ($88.69) target price on Fresenius SE & Co. KGaA (FRA:FRE) in a research note issued to investors on Friday morning. The brokerage currently has a neutral rating on the stock.

FRE has been the topic of a number of other research reports. Morgan Stanley set a €83.00 ($98.81) target price on Fresenius SE & Co. KGaA and gave the company a buy rating in a report on Wednesday, October 4th. Deutsche Bank set a €85.00 ($101.19) target price on Fresenius SE & Co. KGaA and gave the company a buy rating in a report on Tuesday, August 8th. Kepler Capital Markets set a €63.00 ($75.00) target price on Fresenius SE & Co. KGaA and gave the company a neutral rating in a report on Tuesday. UBS set a €74.00 ($88.10) target price on Fresenius SE & Co. KGaA and gave the company a neutral rating in a report on Tuesday, September 19th. Finally, Warburg Research set a €78.00 ($92.86) target price on Fresenius SE & Co. KGaA and gave the company a neutral rating in a report on Monday, October 30th. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Fresenius SE & Co. KGaA has a consensus rating of Buy and a consensus price target of €79.48 ($94.61).

Fresenius SE & Co. KGaA (FRA FRE) traded up €0.16 ($0.19) on Friday, reaching €61.03 ($72.65). The company’s stock had a trading volume of 4,288 shares. Fresenius SE & Co. KGaA has a 12-month low of €60.16 ($71.62) and a 12-month high of €80.00 ($95.24).

WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/02/fresenius-se-74-50-price-target-by-goldman-sachs-group-analysts.html.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Stock Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related stocks with our FREE daily email newsletter.